First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children’s ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-01

AUTHORS

Frank M. Balis, Patrick A. Thompson, Yael P. Mosse, Susan M. Blaney, Charles G. Minard, Brenda J. Weigel, Elizabeth Fox

ABSTRACT

PURPOSE: Characterize the pharmacokinetics of oral crizotinib in children with cancer. METHODS: Sixty-four children with solid tumors or anaplastic large-cell lymphoma (ALCL) enrolled on a phase 1/2 trial of the ALK, MET and ROS1 inhibitor, crizotinib, had pharmacokinetic sampling after the first dose (n = 15) or at steady state (n = 49). Dose levels studied were 100, 130, 165, 215, 280 and 365 mg/m2/dose administered twice daily. Two capsule and two oral liquid formulations were used over the course of the trial. Crizotinib was quantified with a validated HPLC/tandem mass spectrometry method with a lower limit of detection of 0.2 ng/mL. Pharmacokinetic parameters were derived using non-compartmental analysis. RESULTS: Time to peak plasma concentration was 4 h. At 280 mg/m2 (MTD), mean (±SD) steady-state peak plasma concentration was 717 ± 201 ng/mL, and steady-state trough plasma concentration was 480 ± 176 ng/mL. At steady state, AUC0-τ was proportional to dose over the dose range of 215-365 mg/m2/dose. Apparent clearance of crizotinib was 731 ± 241 mL/min/m2. Steady-state AUC0-τ at 280 mg/m2/dose was 2.5-fold higher than the AUC0-∞ in adults receiving 250 mg (~140 mg/m2). Age, sex and drug formulation do not account for the inter-subject variability in AUC0-τ at steady state. The accumulation index was 4.9, and the half-life estimated from the accumulation index was 36 h. CONCLUSIONS: The pharmacokinetics of oral crizotinib in children is similar to that in adults. Steady-state trough-free crizotinib concentrations in plasma at the MTD exceed inhibitory concentrations of crizotinib in ALCL cell lines. CLINICALTRIALS. GOV IDENTIFIER: NCT00939770. More... »

PAGES

181-187

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-016-3220-6

DOI

http://dx.doi.org/10.1007/s00280-016-3220-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1052099870

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28032129


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Oral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child, Preschool", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Crizotinib", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphoma, Large-Cell, Anaplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Kinase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyridines", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Children's Hospital of Philadelphia", 
          "id": "https://www.grid.ac/institutes/grid.239552.a", 
          "name": [
            "The Children\u2019s Hospital of Philadelphia, 3501 Civic Center Blvd, CTRB-4024, 19104, Philadelphia, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Balis", 
        "givenName": "Frank M.", 
        "id": "sg:person.0632613056.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0632613056.56"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of North Carolina at Chapel Hill", 
          "id": "https://www.grid.ac/institutes/grid.10698.36", 
          "name": [
            "University of North Carolina Lineberger Comprehensive Cancer Center, 27599, Chapel Hill, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Thompson", 
        "givenName": "Patrick A.", 
        "id": "sg:person.01320406500.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320406500.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Children's Hospital of Philadelphia", 
          "id": "https://www.grid.ac/institutes/grid.239552.a", 
          "name": [
            "The Children\u2019s Hospital of Philadelphia, 3501 Civic Center Blvd, CTRB-4024, 19104, Philadelphia, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mosse", 
        "givenName": "Yael P.", 
        "id": "sg:person.01161336657.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01161336657.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Baylor College of Medicine", 
          "id": "https://www.grid.ac/institutes/grid.39382.33", 
          "name": [
            "Baylor College of Medicine, Dan L Duncan Comprehensive Cancer Center, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Blaney", 
        "givenName": "Susan M.", 
        "id": "sg:person.0701546277.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0701546277.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Baylor College of Medicine", 
          "id": "https://www.grid.ac/institutes/grid.39382.33", 
          "name": [
            "Baylor College of Medicine, Dan L Duncan Comprehensive Cancer Center, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Minard", 
        "givenName": "Charles G.", 
        "id": "sg:person.01002063145.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01002063145.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Children's Oncology Group", 
          "id": "https://www.grid.ac/institutes/grid.428204.8", 
          "name": [
            "University of Minnesota, Masonic Cancer Center, 55455, Minneapolis, MN, USA", 
            "The Children\u2019s Oncology Group Operations Center, 91016, Monrovia, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Weigel", 
        "givenName": "Brenda J.", 
        "id": "sg:person.01357115675.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01357115675.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Children's Hospital of Philadelphia", 
          "id": "https://www.grid.ac/institutes/grid.239552.a", 
          "name": [
            "The Children\u2019s Hospital of Philadelphia, 3501 Civic Center Blvd, CTRB-4024, 19104, Philadelphia, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fox", 
        "givenName": "Elizabeth", 
        "id": "sg:person.013165332357.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013165332357.81"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1056/nejmoa1408440", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005474865"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jcph.356", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007413773"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40265-013-0142-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013866862", 
          "https://doi.org/10.1007/s40265-013-0142-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmc1013224", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033367810"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2147/pgpm.s37504", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037624927"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(13)70095-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042585366"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.lungcan.2014.12.010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043228159"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1517/17425255.2015.1021685", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046210491"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1535-7163.mct-07-0365", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048386625"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/00498254.2014.941964", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053030203"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(12)70344-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053247125"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-01", 
    "datePublishedReg": "2017-01-01", 
    "description": "PURPOSE: Characterize the pharmacokinetics of oral crizotinib in children with cancer.\nMETHODS: Sixty-four children with solid tumors or anaplastic large-cell lymphoma (ALCL) enrolled on a phase 1/2 trial of the ALK, MET and ROS1 inhibitor, crizotinib, had pharmacokinetic sampling after the first dose (n\u00a0=\u00a015) or at steady state (n\u00a0=\u00a049). Dose levels studied were 100, 130, 165, 215, 280 and 365\u00a0mg/m2/dose administered twice daily. Two capsule and two oral liquid formulations were used over the course of the trial. Crizotinib was quantified with a validated HPLC/tandem mass spectrometry method with a lower limit of detection of 0.2\u00a0ng/mL. Pharmacokinetic parameters were derived using non-compartmental analysis.\nRESULTS: Time to peak plasma concentration was 4\u00a0h. At 280\u00a0mg/m2 (MTD), mean (\u00b1SD) steady-state peak plasma concentration was 717\u00a0\u00b1\u00a0201\u00a0ng/mL, and steady-state trough plasma concentration was 480\u00a0\u00b1\u00a0176\u00a0ng/mL. At steady state, AUC0-\u03c4 was proportional to dose over the dose range of 215-365\u00a0mg/m2/dose. Apparent clearance of crizotinib was 731\u00a0\u00b1\u00a0241\u00a0mL/min/m2. Steady-state AUC0-\u03c4 at 280\u00a0mg/m2/dose was 2.5-fold higher than the AUC0-\u221e in adults receiving 250\u00a0mg (~140\u00a0mg/m2). Age, sex and drug formulation do not account for the inter-subject variability in AUC0-\u03c4 at steady state. The accumulation index was 4.9, and the half-life estimated from the accumulation index was 36\u00a0h.\nCONCLUSIONS: The pharmacokinetics of oral crizotinib in children is similar to that in adults. Steady-state trough-free crizotinib concentrations in plasma at the MTD exceed inhibitory concentrations of crizotinib in ALCL cell lines. CLINICALTRIALS.\nGOV IDENTIFIER: NCT00939770.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00280-016-3220-6", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2705355", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "79"
      }
    ], 
    "name": "First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children\u2019s Oncology Group Phase 1/Pilot Consortium", 
    "pagination": "181-187", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "f82b96c4a8a4b25b522934a230504decc0cd98a34d97d7b1d2c701a86c94342e"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28032129"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7806519"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-016-3220-6"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1052099870"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-016-3220-6", 
      "https://app.dimensions.ai/details/publication/pub.1052099870"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T10:34", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000349_0000000349/records_113664_00000002.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs00280-016-3220-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-016-3220-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-016-3220-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-016-3220-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-016-3220-6'


 

This table displays all metadata directly associated to this object as RDF triples.

213 TRIPLES      21 PREDICATES      54 URIs      35 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-016-3220-6 schema:about N329ed5bfe8ef4208a54dc4c69058db99
2 N647ed0a6fc24426f831e82368b82f7d2
3 N74d3d3f445da4b199694b2efaf0e4388
4 N87bfa9ff41d34e19a433962015bb7808
5 N911f2bed0d2d44dbaec38fd672c4a768
6 N9e9558959c284ee7bb3c369dc995cc55
7 Na3582dace66f4b688e9b90a2f588f714
8 Na8bfe1bd1ab64deab7bb22ac8c3aefda
9 Nbabaeecb73e94194ac363bc0d8fa2f6f
10 Nc1fdd123b9704f078487940dd048c601
11 Neab33ec42ebf43febc499138791d9340
12 Nf00feb55fa994d1d865d317cfe1eee09
13 Nf2876e1283bb463895d22cbde5ac7c49
14 Nffdf455a2ff747e2a83bbc8ac8c7782f
15 anzsrc-for:11
16 anzsrc-for:1112
17 schema:author Nfe156c6fab034ed98ddf92b537fe0723
18 schema:citation sg:pub.10.1007/s40265-013-0142-z
19 https://doi.org/10.1002/jcph.356
20 https://doi.org/10.1016/j.lungcan.2014.12.010
21 https://doi.org/10.1016/s1470-2045(12)70344-3
22 https://doi.org/10.1016/s1470-2045(13)70095-0
23 https://doi.org/10.1056/nejmc1013224
24 https://doi.org/10.1056/nejmoa1408440
25 https://doi.org/10.1158/1535-7163.mct-07-0365
26 https://doi.org/10.1517/17425255.2015.1021685
27 https://doi.org/10.2147/pgpm.s37504
28 https://doi.org/10.3109/00498254.2014.941964
29 schema:datePublished 2017-01
30 schema:datePublishedReg 2017-01-01
31 schema:description PURPOSE: Characterize the pharmacokinetics of oral crizotinib in children with cancer. METHODS: Sixty-four children with solid tumors or anaplastic large-cell lymphoma (ALCL) enrolled on a phase 1/2 trial of the ALK, MET and ROS1 inhibitor, crizotinib, had pharmacokinetic sampling after the first dose (n = 15) or at steady state (n = 49). Dose levels studied were 100, 130, 165, 215, 280 and 365 mg/m2/dose administered twice daily. Two capsule and two oral liquid formulations were used over the course of the trial. Crizotinib was quantified with a validated HPLC/tandem mass spectrometry method with a lower limit of detection of 0.2 ng/mL. Pharmacokinetic parameters were derived using non-compartmental analysis. RESULTS: Time to peak plasma concentration was 4 h. At 280 mg/m2 (MTD), mean (±SD) steady-state peak plasma concentration was 717 ± 201 ng/mL, and steady-state trough plasma concentration was 480 ± 176 ng/mL. At steady state, AUC0-τ was proportional to dose over the dose range of 215-365 mg/m2/dose. Apparent clearance of crizotinib was 731 ± 241 mL/min/m2. Steady-state AUC0-τ at 280 mg/m2/dose was 2.5-fold higher than the AUC0-∞ in adults receiving 250 mg (~140 mg/m2). Age, sex and drug formulation do not account for the inter-subject variability in AUC0-τ at steady state. The accumulation index was 4.9, and the half-life estimated from the accumulation index was 36 h. CONCLUSIONS: The pharmacokinetics of oral crizotinib in children is similar to that in adults. Steady-state trough-free crizotinib concentrations in plasma at the MTD exceed inhibitory concentrations of crizotinib in ALCL cell lines. CLINICALTRIALS. GOV IDENTIFIER: NCT00939770.
32 schema:genre research_article
33 schema:inLanguage en
34 schema:isAccessibleForFree true
35 schema:isPartOf N05db9e2f4a3a4e0fb8a2f2531f9c321c
36 Nda8c25ecef9b4336a21e2346f87087fa
37 sg:journal.1088364
38 schema:name First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children’s Oncology Group Phase 1/Pilot Consortium
39 schema:pagination 181-187
40 schema:productId N2b6d0739cdf34c42a9909429f15bcc74
41 N3583a5f0465e4625a58500e84042d71b
42 Na1bb677ac3064eb98d4d6118e66c7159
43 Nb8f131511a52403f810e37cb5b12d107
44 Nffd464e664cf487686bee9afa23f5f2c
45 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052099870
46 https://doi.org/10.1007/s00280-016-3220-6
47 schema:sdDatePublished 2019-04-11T10:34
48 schema:sdLicense https://scigraph.springernature.com/explorer/license/
49 schema:sdPublisher N1fd81f2b64fd4870815473b42f416b1d
50 schema:url https://link.springer.com/10.1007%2Fs00280-016-3220-6
51 sgo:license sg:explorer/license/
52 sgo:sdDataset articles
53 rdf:type schema:ScholarlyArticle
54 N05db9e2f4a3a4e0fb8a2f2531f9c321c schema:issueNumber 1
55 rdf:type schema:PublicationIssue
56 N0718ccbd73624888a4eeacdafc3d7920 rdf:first sg:person.01357115675.34
57 rdf:rest N75598e74710849fdb54d382d7ea50e8a
58 N1fd81f2b64fd4870815473b42f416b1d schema:name Springer Nature - SN SciGraph project
59 rdf:type schema:Organization
60 N2b6d0739cdf34c42a9909429f15bcc74 schema:name dimensions_id
61 schema:value pub.1052099870
62 rdf:type schema:PropertyValue
63 N329ed5bfe8ef4208a54dc4c69058db99 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
64 schema:name Protein Kinase Inhibitors
65 rdf:type schema:DefinedTerm
66 N3583a5f0465e4625a58500e84042d71b schema:name readcube_id
67 schema:value f82b96c4a8a4b25b522934a230504decc0cd98a34d97d7b1d2c701a86c94342e
68 rdf:type schema:PropertyValue
69 N5805585c2b784d1387ad82d0454a2c10 rdf:first sg:person.01320406500.95
70 rdf:rest N883f1b373db34509853df70922ee143d
71 N647ed0a6fc24426f831e82368b82f7d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
72 schema:name Lymphoma, Large-Cell, Anaplastic
73 rdf:type schema:DefinedTerm
74 N7277c8e792f941bd958226bc5efa1b11 rdf:first sg:person.01002063145.49
75 rdf:rest N0718ccbd73624888a4eeacdafc3d7920
76 N74066517c15246eaafe7d7d9d28f9a82 rdf:first sg:person.0701546277.52
77 rdf:rest N7277c8e792f941bd958226bc5efa1b11
78 N74d3d3f445da4b199694b2efaf0e4388 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name Administration, Oral
80 rdf:type schema:DefinedTerm
81 N75598e74710849fdb54d382d7ea50e8a rdf:first sg:person.013165332357.81
82 rdf:rest rdf:nil
83 N87bfa9ff41d34e19a433962015bb7808 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Adult
85 rdf:type schema:DefinedTerm
86 N883f1b373db34509853df70922ee143d rdf:first sg:person.01161336657.05
87 rdf:rest N74066517c15246eaafe7d7d9d28f9a82
88 N911f2bed0d2d44dbaec38fd672c4a768 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Male
90 rdf:type schema:DefinedTerm
91 N9e9558959c284ee7bb3c369dc995cc55 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Female
93 rdf:type schema:DefinedTerm
94 Na1bb677ac3064eb98d4d6118e66c7159 schema:name doi
95 schema:value 10.1007/s00280-016-3220-6
96 rdf:type schema:PropertyValue
97 Na3582dace66f4b688e9b90a2f588f714 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Child
99 rdf:type schema:DefinedTerm
100 Na8bfe1bd1ab64deab7bb22ac8c3aefda schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Child, Preschool
102 rdf:type schema:DefinedTerm
103 Nb8f131511a52403f810e37cb5b12d107 schema:name pubmed_id
104 schema:value 28032129
105 rdf:type schema:PropertyValue
106 Nbabaeecb73e94194ac363bc0d8fa2f6f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Crizotinib
108 rdf:type schema:DefinedTerm
109 Nc1fdd123b9704f078487940dd048c601 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Adolescent
111 rdf:type schema:DefinedTerm
112 Nda8c25ecef9b4336a21e2346f87087fa schema:volumeNumber 79
113 rdf:type schema:PublicationVolume
114 Neab33ec42ebf43febc499138791d9340 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Pyridines
116 rdf:type schema:DefinedTerm
117 Nf00feb55fa994d1d865d317cfe1eee09 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Humans
119 rdf:type schema:DefinedTerm
120 Nf2876e1283bb463895d22cbde5ac7c49 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Pyrazoles
122 rdf:type schema:DefinedTerm
123 Nfe156c6fab034ed98ddf92b537fe0723 rdf:first sg:person.0632613056.56
124 rdf:rest N5805585c2b784d1387ad82d0454a2c10
125 Nffd464e664cf487686bee9afa23f5f2c schema:name nlm_unique_id
126 schema:value 7806519
127 rdf:type schema:PropertyValue
128 Nffdf455a2ff747e2a83bbc8ac8c7782f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Neoplasms
130 rdf:type schema:DefinedTerm
131 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
132 schema:name Medical and Health Sciences
133 rdf:type schema:DefinedTerm
134 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
135 schema:name Oncology and Carcinogenesis
136 rdf:type schema:DefinedTerm
137 sg:grant.2705355 http://pending.schema.org/fundedItem sg:pub.10.1007/s00280-016-3220-6
138 rdf:type schema:MonetaryGrant
139 sg:journal.1088364 schema:issn 0344-5704
140 1432-0843
141 schema:name Cancer Chemotherapy and Pharmacology
142 rdf:type schema:Periodical
143 sg:person.01002063145.49 schema:affiliation https://www.grid.ac/institutes/grid.39382.33
144 schema:familyName Minard
145 schema:givenName Charles G.
146 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01002063145.49
147 rdf:type schema:Person
148 sg:person.01161336657.05 schema:affiliation https://www.grid.ac/institutes/grid.239552.a
149 schema:familyName Mosse
150 schema:givenName Yael P.
151 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01161336657.05
152 rdf:type schema:Person
153 sg:person.013165332357.81 schema:affiliation https://www.grid.ac/institutes/grid.239552.a
154 schema:familyName Fox
155 schema:givenName Elizabeth
156 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013165332357.81
157 rdf:type schema:Person
158 sg:person.01320406500.95 schema:affiliation https://www.grid.ac/institutes/grid.10698.36
159 schema:familyName Thompson
160 schema:givenName Patrick A.
161 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320406500.95
162 rdf:type schema:Person
163 sg:person.01357115675.34 schema:affiliation https://www.grid.ac/institutes/grid.428204.8
164 schema:familyName Weigel
165 schema:givenName Brenda J.
166 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01357115675.34
167 rdf:type schema:Person
168 sg:person.0632613056.56 schema:affiliation https://www.grid.ac/institutes/grid.239552.a
169 schema:familyName Balis
170 schema:givenName Frank M.
171 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0632613056.56
172 rdf:type schema:Person
173 sg:person.0701546277.52 schema:affiliation https://www.grid.ac/institutes/grid.39382.33
174 schema:familyName Blaney
175 schema:givenName Susan M.
176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0701546277.52
177 rdf:type schema:Person
178 sg:pub.10.1007/s40265-013-0142-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1013866862
179 https://doi.org/10.1007/s40265-013-0142-z
180 rdf:type schema:CreativeWork
181 https://doi.org/10.1002/jcph.356 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007413773
182 rdf:type schema:CreativeWork
183 https://doi.org/10.1016/j.lungcan.2014.12.010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043228159
184 rdf:type schema:CreativeWork
185 https://doi.org/10.1016/s1470-2045(12)70344-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053247125
186 rdf:type schema:CreativeWork
187 https://doi.org/10.1016/s1470-2045(13)70095-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042585366
188 rdf:type schema:CreativeWork
189 https://doi.org/10.1056/nejmc1013224 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033367810
190 rdf:type schema:CreativeWork
191 https://doi.org/10.1056/nejmoa1408440 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005474865
192 rdf:type schema:CreativeWork
193 https://doi.org/10.1158/1535-7163.mct-07-0365 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048386625
194 rdf:type schema:CreativeWork
195 https://doi.org/10.1517/17425255.2015.1021685 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046210491
196 rdf:type schema:CreativeWork
197 https://doi.org/10.2147/pgpm.s37504 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037624927
198 rdf:type schema:CreativeWork
199 https://doi.org/10.3109/00498254.2014.941964 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053030203
200 rdf:type schema:CreativeWork
201 https://www.grid.ac/institutes/grid.10698.36 schema:alternateName University of North Carolina at Chapel Hill
202 schema:name University of North Carolina Lineberger Comprehensive Cancer Center, 27599, Chapel Hill, NC, USA
203 rdf:type schema:Organization
204 https://www.grid.ac/institutes/grid.239552.a schema:alternateName Children's Hospital of Philadelphia
205 schema:name The Children’s Hospital of Philadelphia, 3501 Civic Center Blvd, CTRB-4024, 19104, Philadelphia, PA, USA
206 rdf:type schema:Organization
207 https://www.grid.ac/institutes/grid.39382.33 schema:alternateName Baylor College of Medicine
208 schema:name Baylor College of Medicine, Dan L Duncan Comprehensive Cancer Center, 77030, Houston, TX, USA
209 rdf:type schema:Organization
210 https://www.grid.ac/institutes/grid.428204.8 schema:alternateName Children's Oncology Group
211 schema:name The Children’s Oncology Group Operations Center, 91016, Monrovia, CA, USA
212 University of Minnesota, Masonic Cancer Center, 55455, Minneapolis, MN, USA
213 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...